Global Irritable Bowel Syndrome Treatment Market by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others), Medical Condition (IBS-constipation and IBS-diarrhea), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) and Region - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025
- Report code : CMI6506 |
- Industry :
Pharmaceutical
- Published On : Oct 2017 |
- Pages : 194 Pages |
- Format :
Irritable Bowel Syndrome - Don’t Just Trust Your Gut
Irritable bowel syndrome is a gastrointestinal tract disorder characterized by abdominal pain and altered bowel habits. It hampers the natural movement of intestinal muscle linings to move food along the digestive tract. Depending on the symptoms, the syndrome is distinguished as mild and severe irritable bowel syndrome. These symptoms include cramping, abdominal pain, bloating and gas, mucus in the stool, constipation, and diarrhea. Exact cause of occurrence of irritable bowel syndrome is unknown though, it is associated with increased awareness of bodily functions, and abnormal gastrointestinal tract movements. Diagnosis of irritable bowel syndrome is done by tests such as blood tests, stool tests, endoscopic procedures and external imaging procedures. Patients suffering from irritable bowel syndrome may experience complications namely, deep ulcerations, infections, and malnutrition and bowel obstructions. Treatment of irritable bowel syndrome involves relieving the patient from the symptoms and improving the quality of life.
Robust pipeline with symptom specific indications and subsequent launches in the forecast period is expected to boost the market
According to International Foundation for Functional Gastrointestinal Disorders, 2016, worldwide prevalence of irritable bowel syndrome is around 10-15%. Furthermore, there are between 2.4 and 3.5 million annual physician visits for IBS in the U.S. according to the same source. According to the Anxiety and Depression Association of America, approximately one in five adults in the U.S. is suffering with irritable bowel syndrome. Irritable bowel syndrome shows a wide range of symptoms, so, the treatment is decided on predominance of the symptoms such as, in pain predominant patients, antispasmodic agents or tricyclic antidepressants are used. The prevalence of irritable bowel syndrome is predominant in female than in males. According to the International Foundation for Functional Gastrointestinal Disorders, 2 in 3 IBS sufferers are female. Some of the U.S. Food & Drug Administration approved drugs for relieving the symptoms associated with IBS are Lotronex (Alosetron), Amitiza (Lubiprostone), Linzess (Linclotide), and Xifaxan (Rifaximin).
The global irritable bowel syndrome treatment market was valued at US$ 726.1 million in 2016 and is expected to witness a robust CAGR of 12.9% over the forecast period (2017-2025).
Table 1. Irritable Bowel Syndrome Drugs Pipeline
| Drug/ Candidate/Bacterial Strain | Phase |
| Blautix (Strain) | Phase 1b |
| Bekinda (IBS-D) | Phase 2 |
| SYN-010 | Phase 2 |
| Tenapanor | Phase 3 |
Source: clincaltrials.gov
Increase in levels of stress and adoption of sedentary lifestyle is expected to increase the prevalence of lifestyle disorders namely irritable bowel syndrome
The number of available irritable bowel syndrome drugs has increased over the last few years and new drugs have been approved for the treatment. North America accounts for the largest share in the global irritable bowel syndrome treatment market, followed by Europe and Asia-pacific, respectively. According to an article published in the Brandon Gaille in 2017, on an average, junk food accounts for 28.8% of the total caloric intake of an American. According to Centers for Disease Control and Prevention (CDC) in 2015, it was estimated that 1.3% of U.S. adults i.e. 3 million were reported to being diagnosed with IBD. Consumption of unhealthy food in large quantities raises the bar of probability for IBS acting as a driving factor for the global market growth. Furthermore, the companies are indulged in development, distribution and marketing agreements of irritable bowel syndrome treatment drugs in selective countries such as Japan and China which is expected to drive the growth of the Asia-Pacific irritable bowel syndrome treatment market. For, instance, Sucampo Pharmaceutical, Inc. collaborated with Herbin Gloria Pharmaceuticals to commercialize its product in China in 2015.
Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.
The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.
Market Dynamics
The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.
Market Taxonomy
This report segments the global irritable bowel syndrome treatment market on the basis of drug type, medical condition, and distribution channel. On the basis of drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.
Key features of the study:
- This report provides in-depth analysis of irritable bowel syndrome treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global irritable bowel syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Abbott Laboratories*, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., Ironwood Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Irritable Bowel Syndrome Treatment Market
Detailed Segmentation:
- Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global Irritable Bowel Syndrome Treatment Market, By Geography:
- North America
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.S.
- Canada
- Europe
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.K.
- Italy
- Spain
- Russia
- Rest of Europe
- Asia-Pacific
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- China
- Japan
- ASEAN
- Rest of Asia Pacific
- Latin America
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- Mexico
- Rest of Latin America
- Middle East
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- By Medical Condition:
- IBS-Constipation
- IBS-Diarrhea
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- South Africa
- Rest of Africa
- Company Profiles
- Abbott Laboratories *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- Synergy Pharmaceuticals, Inc.
- Sucampo Pharmaceuticals, Inc.
- Valeant Pharmaceuticals International, Inc.
- Ardelyx, Inc.
- Astellas Pharma Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Ironwood Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Drug Type
- Market Snippet By Medical Condition
- Market Snippet By Distribution Channel
- Market Snippet By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Consumer Trends
- Impact Analysis
- FDA Approval Timeline
- PEST Analysis
- Probiotics & Prebiotics
- Global Irritable Bowel Syndrome Treatment Market, By Drug Type, 2017 - 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 - 2025
- Segment Trends
- Lubiprostone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Linaclotide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Eluxadoline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Rifaximin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Ramosetron Hydrochloride
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Global Irritable Bowel Syndrome Treatment Market, By Medical Condition, 2017 - 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 - 2025
- Segment Trends
- IBS - Constipation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- IBS - Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 - 2025
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Mn)
- Global Irritable Bowel Syndrome Treatment Market, By Regions, 2017 - 2025 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2025
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- U.K.
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- China
- Japan
- ASEAN
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- Mexico
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- South Africa
- Rest of Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2025 (US$ Mn)
- Israel
- Rest of Middle East
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Synergy Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sucampo Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Valeant Pharmaceuticals International, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Ardelyx, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Ironwood Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 43 market data tables and 34 figures on "Irritable Bowel Syndrome Treatment Market - Global forecast to 2025”.
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.